Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Average Rating of “Moderate Buy” from Brokerages

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has earned an average rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $48.00.

Several research analysts have commented on the stock. HC Wainwright upped their price objective on shares of Hemab Therapeutics from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, July 13th. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price on the stock. Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Finally, Wedbush restated an “outperform” rating and issued a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a report on Monday, July 13th.

Hemab Therapeutics Stock Performance

Shares of Hemab Therapeutics stock opened at $49.29 on Friday. The company has a market capitalization of $2.30 billion and a P/E ratio of -2.06. The company’s 50 day simple moving average is $30.22. Hemab Therapeutics has a 52 week low of $23.00 and a 52 week high of $50.11.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Activity

In other news, Director Ra Capital Management, L.P. bought 2,675,000 shares of the stock in a transaction dated Monday, May 4th. The stock was bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the purchase, the director directly owned 6,149,096 shares in the company, valued at $110,683,728. This trade represents a 77.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders purchased 2,970,541 shares of company stock valued at $55,459,603.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.